newsfilter
← Latest News
GlobeNewswire·

Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis

– Trial did not meet the primary endpoint of annualized rate of FVC decline – – Axatilimab was well tolerated with a safety profile comparable to placebo; no new safety signals were observed – – Axatilimab continues